Navigation Links
aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Date:8/14/2013

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- aTyr Pharma, an innovative disease therapeutics enterprise, announced today the expansion of the company's executive leadership team. Ms. Kelly Blackburn joins aTyr as vice president, Clinical Affairs. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases. aTyr is advancing a therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immunology.

(Logo: http://photos.prnewswire.com/prnh/20120809/MM55538LOGO)

"At this key point in aTyr's evolution, the expansion of our executive leadership will help advance our first therapeutic program into the clinic in rare diseases," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. "Ms. Blackburn has more than 20 years of experience in managing and leading clinical programs, including the development of innovative molecules for rare diseases.  We look forward to Kelly's leadership as we work to rapidly translate our leading research in new Physiocrine biology into therapeutics for patients with grave immune diseases."

Ms. Blackburn was formerly the vice president, Clinical Development Operations at Vertex Pharmaceuticals where she was responsible for the operational plans and strategy for the full product portfolio including two transformational programs, KalydecoTM and Incivek®. Prior to Vertex, she was director, Clinical and Safety Operations at Millenium Pharmaceuticals, where she was operationally responsible for the lead product, VELCADE®.  Previous to that, she held several clinical operations roles of increasing responsibility at Vertex, Genetics Institute and Bayer Corporate. Ms. Blackburn received her B.S. in biochemistry from University of New Hampshire, MHA from Quinnipiac College and M.Ed. from Cambridge College.

About Physiocrines

Physiocrines act as extracellular signaling molecules to orchestrate cellular homeostasis in response to stress. Physiocrines are naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and the resolution of inflammation. As potent endogenous modulators of inflammation, Physiocrines offer the opportunity for modulating biological pathways through new naturally occurring mechanisms, many of which have multiple therapeutic advantages, including improved selectivity, efficacy and reduced side effect profiles compared to many existing anti-inflammatory therapeutics.

About aTyr Pharma

aTyr Pharma has developed an extensive pipeline of future therapeutic products based on Physiocrine biology. aTyr has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr's key programs are currently focused on rare immunomodulation disorders in the areas of inflammation and immunity. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
4. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
5. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
6. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
7. PipelineRx Announces Telepharmacy Contract with GNYHA Services
8. Emdeon Continues Focus on Patient-Centered Healthcare Solutions; Renews Chain Drug Consortium Contract for Multiple Pharmacy Solutions
9. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
10. Valeant Pharmaceuticals Announces Continuance
11. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):